Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.52 +0.44 (+0.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
28 29 Next >
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday, 52 stocks hit new 52-week lows. 
Via Benzinga
Sanofi (NASDAQ:SNY) Shareholder Notice: Investigation Concerning Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 08/09/2022 -- Sanofi is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Monkeypox Plays Jockey For Position This Week
Via AB Newswire
Exposures COVID-19 Product Safety
Sanofi, Innovent Biologics Collaborate On Cancer Treatments In China
Via Benzinga
Sanofi Ekes Out Narrow Beat As Eczema Giant Scores Massive Gain
The company reported more than 40% growth for Dupixent in the second quarter. 
Via Investor's Business Daily
Sanofi Raises Annual Guidance On Upbeat Q2 Performance
Via Benzinga
Daily Stock Analysis: Sanofi S.A.
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. It was founded in 1973 and is headquartered in Paris. 
Via Talk Markets
Looking Into Sanofi's Recent Short Interest
Sanofi's (NASDAQ:SNY) short percent of float has fallen 25.0% since its last report. The company recently reported that it has 2.31 million shares sold short, which is 0.09% of... 
Via Benzinga
How Siga Is Turning Its Biowarfare Soldier Onto This Outbreak ... And The Next
Siga stock more than tripled, emerging from under the radar to take on the outbreak. 
Via Investor's Business Daily
Regeneron's Prostate Cancer Combo Candidate Shows Encouraging Anti-Tumor Activity
Via Benzinga
A Bearish Sign Appears On Sanofi's Chart
If history is any guide, there may be trouble ahead for shares of Sanofi (NASDAQ:SNY). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock. 
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
3-D Portfolio: Discounts, Diversification, And Dividends
When it comes to high-yield closed-end funds, I’m a big fan of the “three Ds” — discounts, diversification, and dividends. Today, we’ll look at a three-fund, bargain-priced “3-D” CEF portfolio you can... 
Via Talk Markets
Week In Review: China Biopharma Tops $2.8 Billion In Week's Dealmaking
CSPC Pharma out-licensed global rights for its antibody drug conjugate targeting Claudin18.2 to Elevation Oncology of New York City. CSPC will receive a $27 million upfront payment and up to $148... 
Via Talk Markets
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
A Monoclonal Antibody Treatment For ALS Could Begin Human Trials By 2023, According To Pasithea
Pasithea Therapeutics Corp. (NASDAQ: KTTA), a biotech company looking for new treatments for psychiatric and neurological disorders, received an AU$1 million (US$694,000) gran 
Via Benzinga
Earnings Scheduled For July 28, 2022
Companies Reporting Before The Bell • ArcelorMittal (NYSE:MT) is estimated to report earnings for its second quarter. 
Via Benzinga
Earnings Outlook For Sanofi
Sanofi (NASDAQ:SNY) is set to give its latest quarterly earnings report on Thursday, 2022-07-28. Here's what investors need to know before the announcement. Analysts estimate that Sanofi will report an... 
Via Benzinga
Regeneron's Price Target Cut On Dim Prospects For Its Flagship Eye Product
Via Benzinga
Amid RNA Setbacks, Start Up Bets On Sanofi's siRNA Platform
Via Benzinga
Apple, Meta, Pfizer Among Key Companies Reporting In The Week Ahead, As Earning Picks Up Pace
Big tech earnings will flow in thick and fast in the upcoming week, providing more clarity on how supply chain disruptions and the macroeconomic malaise have impacted these companies. 
Via Benzinga
Pasithea's Latest Drug Candidate Could Bring New Hope To ALS Patients Without Effective Treatment Options
Amyotrophic lateral sclerosis (ALS) is a rare but painful and fatal disease that slowly shuts down all voluntary movements in the body, from walking to breathing. 
Via Benzinga
Analyzing Sanofi's Short Interest
Sanofi's (NASDAQ:SNY) short percent of float has fallen 14.29% since its last report. The company recently reported that it has 3.00 million shares sold short, which is 0.12% of... 
Via Benzinga
Clovis Oncology (CLVS) Stock Pops 7% on Supply Agreement
CLVS stock is rallying 7% after Clovis Oncology made a major deal with NorthStar Medical. Takeover speculation has swirled around Clovis. 
Via InvestorPlace
The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Regeneron-Sanofi's Dupixent Hits Primary Goal In Esophagitis Patients Below 11 Years
Via Benzinga
Sanofi Offloads 17 Products To Neuraxpharm
Sanofi SA (NASDAQ: SNY) has entered a deal to hand over 17 products to central nervous system (CNS) specialist Neuraxpharm for an undisclosed sum.  
Via Benzinga
The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
SOBI-Sanofi Partnered Hemophilia Therapy Shows Superior Bleed Protection Than Prior Prophylaxis
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
28 29 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.